7. Examination of novelty
7.1 Second or further medical use of known pharmaceutical products
|
A revised version of this publication entered into force. |
How the novelty of second or further medical use claims is assessed depends on the IPEA. The examiner at the EPO as IPEA examines the novelty of the subject-matter in view of the entry into the regional phase before the EPO and therefore will apply the principles as laid down in GL/EPO G‑VI, 7.1 and subsections. See GL/PCT‑EPO B‑VIII, 2.1, for the treatment of medical use claims by the EPO as ISA.